Found 62 matching trials
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
PHASE2This is a non-randomized, prospective, single-group longitudinal study. The...
Location
Helen Diller Family Comprehensive Cancer Center University of California
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
PHASE2The best drug sequencing of dacomitinib or osimertinib in patients with adv...
Location
Istituto Toscano Tumori Ospedale San Donato
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
PHASE3A randomized, open-label assessor blinded, multi-center, controlled phase I...
Location
Institut Bergonié
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
PHASE2This study is designed to explore the potential of the epigenetic agent RRx...
Location
Stanford University
CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk
PHASE2The purpose of this study is to evaluate the safety and feasibility of a tr...
Location
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
PHASE1The purpose of this study is to confirm the tolerability of recommended Pha...
Status
Active Not Recruiting
Location
USC Norris Comprehensive Cancer Center
Italian Treatment Free Remission Registry
N/AThe investigator propose an extension of the previous National, multicentri...
Location
Division of Hematology-AO Mauriziano Hospital, University of Turin
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
PHASE2This study aims to test if patients achieving a tumor response with the com...
Location
Azienda Ospedaliera Universitaria di Cagliari- P.O. Duilio Casula Monserrato
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
PHASE1This was an open-label, Phase 1/2, dose escalation and signal finding study...
Location
Scottsdale Healthcare Research Institute
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
N/ATo investigate whether patients with chronic-phase chronic myeloid leukemia...
Location
University of Michigan Cancer Center